Affle 3i Ltd Secures INR 3,325 Million from Promoter Warrant Exercise

INR 3,325.10 million received in latest remittance; total infusion hits INR 6,115.04 million.

Reader Takeaway: Promoter confidence signals long-term growth, though shareholders should watch for equity dilution post-allotment of new shares.

What just happened

Affle 3i Ltd has successfully processed a remittance of USD 34.99 million (INR 3,325.10 million) from its promoter, Affle Holdings Pte. Ltd. This payment pertains to the second exercise of convertible warrants, following the initial allotment of 7.4 million warrants on June 18, 2026. The company confirmed the receipt in a formal exchange filing on October 16, 2026.

Why this matters

Continuous capital infusion via the warrant route serves as a strong indicator of promoter commitment to the company's business strategy. By converting these warrants into equity, the promoter is essentially increasing their stake and providing the company with immediate liquidity. This total inflow of over INR 6,115 million strengthens the balance sheet, providing the company with resources for operational expansion and strategic scaling.

The backstory

The conversion process began in mid-2026 when the company allotted 7.4 million convertible warrants. The company previously saw a minor exercise of warrants in August 2026, followed by this significantly larger second tranche. The total funds received now include the initial subscription money and subsequent exercise payments, totaling approximately USD 64.49 million.

What to track next

Investors should closely monitor the subsequent regulatory filings regarding the official allotment of the resulting equity shares. Once the shares are allotted, the total outstanding share count of the company will increase. Shareholders should assess how this dilution impacts the earnings per share (EPS) and overall return ratios in the upcoming quarterly reports.